Arcus
Gilead and Arcus Report Positive Results for TIGIT Approach in Gastric Cancer Trial
Gilead; Arcus; TIGIT; Gastric Cancer; Domvanalimab; Zimberelimab
Arcus Biosciences Advances Promising Kidney Cancer Drug Casdatifan After Gilead Opts Out
Arcus Biosciences, casdatifan, HIF-2a inhibitor, kidney cancer, clear cell renal cell carcinoma (ccRCC), Gilead Sciences, clinical trial data, $150 million stock offering
Arcus Biosciences Reveals Positive Data from Terminated TIGIT Combo Trial, Supporting Future Development
Arcus Biosciences, TIGIT combo, domvanalimab, zimberelimab, cancer treatment, clinical trials
Gilead Expands Arcus Collaboration with $320M Equity Investment
Investments, Arcus, Gilead, Combined, Phase 3 Clinical Trials